US FDA classifies Sun Pharma Baska facility as OAI after inspection

Regulatory & Legal View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹1789.50

prior close

₹1785.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.1%-2.4% vs market

Pharmaceuticals peers, median of 152sector-0.4%-2.0% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty 100 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.8

10m

-1.8

15m

-1.8

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4-0.1-2.4-0.4-2.0

Next day

-2.5+0.6-3.0+0.6-3.0

-1.0+1.3-2.3+1.0-2.0

-2.0+1.4-3.4+1.1-3.1

-2.9+1.3-4.1+1.0-3.9

-3.9+0.9-4.8+0.6-4.5

-3.9+0.5-4.4-0.2-3.7

15d

-2.9-0.3-2.6-0.3-2.7

-6.4-0.6-5.8-2.6-3.8

-3.6+0.5-4.1-2.4-1.2

-0.4-7.2+6.8-9.0+8.5

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Sun Pharma's Baska facility from 8-19 September 2025 and classified it as Official Action Indicated (OAI). OAI is the most adverse classification and can lead to warning letters or import alerts. The company says it will keep manufacturing and supplying approved products from this facility to the US market and will work with the regulator to achieve full compliance.

Likely market impact

Negative: may invite FDA warning letter or import alert, risking US supply disruption and revenue impact. Short-term sentiment likely weak.